Opportunity to Switch from Warfarin to a Direct Oral Anticoagulant (DOAC)

This webpage is to inform you about a potential change to your anticoagulation (blood-thinning) treatment. After reviewing your medical records, we believe you may benefit from switching from Warfarin to a newer medication called a Direct Oral Anticoagulant (DOAC), such as rivaroxaban or apixaban (click here for more detailed information on these DOACs).  These are new anticoagulants that are now preferred for the reasons below:


No regular INR blood tests: Unlike warfarin, DOACs do not require frequent INR monitoring or dose adjustments.  
Simpler dosing: Most DOACs are taken once or twice daily at a fixed dose.  
Equivalent effectiveness: DOACs are as effective as Warfarin at preventing strokes in conditions like atrial fibrillation, with a comparable or lower risk of serious bleeding.  
Fewer interactions: DOACs have fewer dietary restrictions and drug interactions compared to Warfarin.  

Is a DOAC right for you?
DOACs are not suitable for everyone. For example, they are not recommended for patients with mechanical heart valves or certain severe kidney conditions. Your GP will review your medical history to confirm eligibility.  

Next Steps
If you are interested in exploring this option, please contact the practice to arrange a consultation with one of our clinical Pharmacists. During this appointment, we will discuss your preferences, assess suitability, and address any questions.  

If you prefer to continue Warfarin, that is entirely acceptable—we will ensure your care remains consistent.  

Final note
This switch is entirely voluntary, and your safety and comfort are our priority. Please do not make any changes to your medication without consulting us first.  

We look forward to hearing from you.  

Yours sincerely,  

Robin Conibere
Lead PCN Pharmacist

Beacon Medical Group


This guidance aligns with current NHS guidelines and NICE recommendations (e.g., NG196, 2021).